Positron (OTCMKTS:POSC – Get Free Report) is one of 78 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its rivals? We will compare Positron to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, risk, dividends, profitability and earnings.
Valuation and Earnings
This table compares Positron and its rivals revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Positron | $740,000.00 | -$1.64 million | -12.13 |
Positron Competitors | $992.46 million | $83.13 million | 9.84 |
Positron’s rivals have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
Volatility & Risk
Positron has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Positron’s rivals have a beta of 0.92, suggesting that their average stock price is 8% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for Positron and its rivals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Positron | 0 | 0 | 0 | 0 | N/A |
Positron Competitors | 287 | 826 | 2136 | 109 | 2.62 |
As a group, “Electromedical equipment” companies have a potential upside of 2,878.01%. Given Positron’s rivals higher possible upside, analysts plainly believe Positron has less favorable growth aspects than its rivals.
Profitability
This table compares Positron and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Positron | -300.00% | N/A | -89.57% |
Positron Competitors | -299.08% | -83.96% | -27.59% |
Summary
Positron rivals beat Positron on 8 of the 10 factors compared.
About Positron
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
Receive News & Ratings for Positron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Positron and related companies with MarketBeat.com's FREE daily email newsletter.